Go to Contents

SILLAJEN

ENG
Notice & News Targeting, Attacking, and Eradicating Cancers®

TOP
IR/PR
Notice & News

Notice & News

게시판
SillaJen Announces First Patient Enrolled in Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron’s Cemiplimab 2018-06-20

SillaJen Announces First Patient Enrolled in Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron’s Cemiplimab 

Link address : https://www.prnewswire.com/news-releases/sillajen-announces-first-patient-enrolled-in-renal-cell-carcinoma-trial-with-pexa-vec-in-combination-with-regenerons-cemiplimab-300669186.html

Prev SillaJen and Lee's Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in China Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer Next SillaJen Poster Presentation at 2018 GU ASCO Symposium Highlights New Clinical Data in RCC, Intravenous Delivery of Pexa-Vec, Oncolytic Immunotherapy List